<DOC>
	<DOCNO>NCT00277095</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness minimally invasive surgical procedure 109 male patient . The ProACT device design treat men stress urinary incontinence arise intrinsic sphincter deficiency follow operation perform prostate cancer benign prostatic hyperplasia . Two adjustable balloon ( one side urethra ) implant treat urinary stress incontinence . The result analyze demonstrate effect device well associated risk . Therapeutic success base whether patient demonstrate least 50 % reduction pad weight 18 month follow-up compare pad weight result baseline .</brief_summary>
	<brief_title>ProACT Therapy Treatment Stress Urinary Incontinence Males</brief_title>
	<detailed_description>The study prospective , non-randomized multi-center investigation . Multiple measurement use 24 hour pad weight pad count , validate questionnaire , void diary use evaluate achievement study objective . Subjects follow minimum 18 month follow implantation . Subjects request continue annual follow-up FDA approval . The purpose study evaluate safety effectiveness minimally invasive surgical procedure 109 male patient . The ProACT device design treat men stress urinary incontinence arise intrinsic sphincter deficiency follow operation perform prostate cancer benign prostatic hyperplasia . Two adjustable balloon ( one side urethra ) implant treat urinary stress incontinence . The result analyze demonstrate effect device well associated risk . Therapeutic success base whether patient demonstrate least 50 % reduction pad weight 18 month follow-up compare pad weight result baseline .</detailed_description>
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Undergone either radical prostatectomy , transurethral resection prostate prostate surgery least 12 month prior without radiation therapy Demonstrate primary stress urinary incontinence Male subject least 45 year age Willing able undergo surgical implantation ProACT device Willing able comply followup requirement Willing able forego surgical urinary incontinence treatment participate study Willing able sign inform consent Positive 24 hour pad weight test ( great equal 8 gram pad weight increase demonstrate two 24hour pad weight test ) Experiences least 3 incontinence episode per day two baseline void diary . Negative Urine culture No recurrent stricture anastamosis No known urogenital malignancy previously treat prostate cancer Physician determine subject suitable surgical candidate Primarily Urge incontinence Detrusor instability overactivity Residual volume great 100 ml great 25 % total bladder capacity voiding . Subject has/had suspect bladder cancer History recurrent bladder stone Neurogenic bladder atonic detrusor sphincter dyssynergia Known hemophilia bleed disorder Abnormal PSA ( Prostate Specific Antigen ) , accord site laboratory standard , unless investigation confirms underlie prostate malignancy . Known sever contrast solution allergy Has genitourinary mechanical prosthesis previous sling procedure ( e.g. , Artificial Urinary sphincter , implantable penile prosthesis ) Has urethral stricture prevents passage 18 F cystoscope one urethrotomy Undergone bulking procedure within 6 month baseline assessment Subject currently enrol plan enroll another device drug clinical trial . Subject currently use indwell catheter condom catheter treatment incontinence willing discontinue use least 4 week prior baseline assessment .</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Urinary Incontinence</keyword>
</DOC>